Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications

2003 ◽  
Vol 29 (3) ◽  
pp. 207-222 ◽  
Author(s):  
JP Riveline ◽  
N Danchin ◽  
F Ledru ◽  
M Varroud-Vial ◽  
G Charpentier
Keyword(s):  
Experimental Data ◽  
Cardiovascular Effects ◽  
Clinical Applications ◽  
Clinical Use

Optimisation of the drill-in behaviour of the EcoFit® SC threaded cup

2020 ◽  
Vol 65 (4) ◽  
pp. 477-484
Author(s):  
Christoph Thorwächter ◽  
Matthias Woiczinski ◽  
Inês Santos ◽  
Florian Schmidutz ◽  
Alexander Paulus ◽  
...  
Keyword(s):  
Three Dimensional ◽  
Primary Stability ◽  
Clinical Results ◽  
Clinical Applications ◽  
Testing System ◽  
Clinical Use ◽  
Maximum Torque ◽  
3D Images ◽  
Universal Testing ◽  
Biomechanical Investigation

AbstractThreaded cups show good clinical results when implanted correctly. In clinical use, multiple cases with an incomplete placement of the EcoFit threaded cup (implantcast) were observed. This behaviour could not be explained intra- and postoperatively. The aim of this study was to compare and optimise the drill-in-behaviour of the EcoFit cup in a biomechanical investigation. EcoFit cup sizes 46, 50 and 54 mm were compared with the SC cup (Aesculap) size 50 mm. Foam blocks (Sawbones) of density 0.16 g/ml (pcf 10), 0.32 g/ml (pcf 20) and 0.48 g/ml (pcf 30) were used. After standardised placement using a universal testing system (n = 8 per group), the primary stability, the overhang of the cups and the drill-in behaviour were measured. Overreamings of 1 and 2 mm were performed (pcf 20, n = 8) for the EcoFit cup size 50 and the primary stability as well as the overhang measurements were examined. Measurements of the cup diameter, thread depth and thread pitch were performed on three-dimensional (3D) images of the cup size 50 mm. The drill-in behaviour was different between the EcoFit and the SC cups. Even with maximum torque, the EcoFit cup could not be positioned as deep as the SC cup in standard reaming conditions (overhang of 1.1 ± 0.4 mm for the EcoFit size 50 in pcf 20 and of −0.01 ± 0.2 mm for the SC cup). The primary stability was lower for the EcoFit cup in comparison to the SC cup (128.8 ± 3.2 Nm vs. 138.6 ± 9.1 Nm, p = 0.0291). With overreaming to 51 mm, a deeper positioning of the EcoFit was possible (overlap of −0.3 ± 0.1, comparable to the SC cup). The overreaming of the cavity also led to a significantly higher primary stability of 143.4 ± 3.7 Nm (p < 0.001) comparable to the unaltered condition (128.8 ± 3.2 Nm). Overreaming to 52 mm had no further advantage in terms of primary stability or overhang. The geometric measurements showed significant differences as well. The previously clinically observed difficulties in inserting the cup were confirmed by this study. By overreaming to 51 mm, the drill-in behaviour, the primary stability and the measured overhang were comparable to the reference cup. The obtained results suggest that the extension of the acetabulum cavity to 51 mm while using the implantcast EcoFit size 50 should be implemented in clinical applications.

scholarly journals Advances in the automated synthesis of 6-[18F]Fluoro-L-DOPA

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Ângela C. B. Neves ◽  
Ivanna Hrynchak ◽  
Inês Fonseca ◽  
Vítor H. P. Alves ◽  
Mariette M. Pereira ◽  
...  
Keyword(s):  
Large Scale ◽  
Neuroendocrine Tumours ◽  
Radiochemical Yield ◽  
Clinical Applications ◽  
Clinical Use ◽  
Molar Activity ◽  
Neuropsychiatric Diseases ◽  
Recent Developments ◽  
Key Issues ◽  
Improved Methods

AbstractThe neurotracer 6-[18F] FDOPA has been, for many years, a powerful tool in PET imaging of neuropsychiatric diseases, movement disorders and brain malignancies. More recently, it also demonstrated good results in the diagnosis of other malignancies such as neuroendocrine tumours, pheochromocytoma or pancreatic adenocarcinoma.The multiple clinical applications of this tracer fostered a very strong interest in the development of new and improved methods for its radiosynthesis. The no-carrier-added nucleophilic 18F-fluorination process has gained increasing attention, in recent years, due to the high molar activities obtained, when compared with the other methods although the radiochemical yield remains low (17–30%). This led to the development of several nucleophilic synthetic processes in order to obtain the product with molar activity, radiochemical yield and enantiomeric purity suitable for human PET studies.Automation of the synthetic processes is crucial for routine clinical use and compliance with GMP requirements. Nevertheless, the complexity of the synthesis makes the production challenging, increasing the chance of failure in routine production. Thus, for large-scale clinical application and wider use of this radiopharmaceutical, progress in the automation of this complex radiosynthesis is of critical importance.This review summarizes the most recent developments of 6-[18F]FDOPA radiosynthesis and discusses the key issues regarding its automation for routine clinical use.

scholarly journals Towards the Immunogenic Hyperthermic Action: Modulated ElectroHyperthermia

2020 ◽  
pp. 1-6
Author(s):  
Andras Szasz ◽  
Andras Szasz
Keyword(s):  
Cancer Cells ◽  
Solid Tumors ◽  
Phase Ii ◽  
Immune Cells ◽  
Genetic Information ◽  
Clinical Applications ◽  
Clinical Use ◽  
Hyperthermia Treatment ◽  
Broad Perspective ◽  
Trade Name

Hyperthermia treatment for solid tumors is a long-used, but poorly accepted method in clinical use. Modulated electro-hyperthermia (mEHT, trade name: oncothermia®) changes the paradigm, introduces a novel, cellularly selective and immunogenic cell-ruination. The mEHT method produces tumor-vaccination, presenting the unharmed genetic information of cancer cells to immune cells [1]. The mEHT method is approved in more than 30 countries. Its phase II/III clinical applications indicate a broad perspective.

Analytical performance goals for measuring prostate-specific antigen

1993 ◽  
Vol 39 (7) ◽  
pp. 1525-1529 ◽  
Author(s):  
H A Fritsche ◽  
R J Babaian
Keyword(s):  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Clinical Decision ◽  
Clinical Applications ◽  
Analytical Performance ◽  
Performance Goals ◽  
Clinical Use ◽  
Psa Test ◽  
Decision Points ◽  
Medical Relevance

Abstract We have assessed the feasibility of using fixed-limit criteria based on medical relevance and biological variation for evaluating the analytical performance of the prostate-specific antigen (PSA) test. The estimated within-subject variation of serum PSA is on the order of 10-20% at clinical decision points. The calculated performance goals of 5-10% CV are attainable with current immunoassay technology and agree with precision goals based on clinical experience and the current clinical use of the test. However, new clinical applications of PSA may require a degree of analytical performance that current methods may not be able to provide. The PSA model demonstrates the need for biologically based fixed-limit criteria for all tumor-marker tests.

scholarly journals Neridronate: From Experimental Data to Clinical Use

2017 ◽  
Vol 9 ◽  
pp. 1179559X1773297
Author(s):  
Addolorata Corrado ◽  
Ripalta Colia ◽  
Francesco Paolo Cantatore
Keyword(s):  
Experimental Data ◽  
Clinical Use

Perioperative Ultrasonography Review

2016 ◽  
Vol 4 (1) ◽  
pp. 3-9
Author(s):  
Nicholas J Schott ◽  
Christopher K Schott
Keyword(s):  
Patient Care ◽  
Assessment Tool ◽  
Point Of Care ◽  
Modern Medicine ◽  
Clinical Applications ◽  
Ease Of Use ◽  
Clinical Use ◽  
Patient Assessment ◽  
Point Of Care Ultrasonography ◽  
Device Technology

ABSTRACT Point-of-care ultrasonography (POCUS) has become increasingly utilized in modern medicine. Advancements in device technology and ease of use have dramatically broadened its clinical applications. The role in acute care specialties of a pointof- care device has allowed increased opportunities for patient assessment and management. The specialties of emergency medicine and critical care medicine have accepted POCUS in many aspects of clinical use as well as trainee education. Anesthesiology has begun to implement the use of POCUS, specifically transthoracic echocardiography, in the perioperative setting. Many elements of patient care can be addressed and modified using this as an assessment tool. This has led to in growth in ultrasonography training and the potential to be a staple of future anesthesiology care. Point-of-care ultrasonography may become vital to the forefront of management for improving perioperative patient care. How to cite this article Schott NJ, Schott CK. Perioperative Ultrasonography Review. J Perioper Echocardiogr 2016; 4(1):3-9.

Sign in / Sign up

Export Citation Format

Share Document